Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

Constrictive bronchiolitis obliterans is an important respiratory illness because of its underlying irreversible fibrotic process, and is defined as concentric fibrosis in the bronchiolar ...

Bristol-Myers Squibb (BMS) has been steadily building its position in fibrotic diseases ... FibroGen's connective tissue growth factor (CTGF) blocker FG-3019. Pharma's interest in fibrosis stems ...

Idiopathic Pulmonary Fibrosis (IPF) is a frightening, incurable disease where the lungs become ... which targets connective tissue growth factor, failed to produce an improvement compared with ...

The therapy showed a ‘favourable’ safety profile both as a single agent and in combination with standard-of-care treatment.

After excluding malignancies, connective tissue ... and the disease was controlled again after adjusting the prednisone dose to 7.5 mg, with no recurrence since. Complications of IgG4-RD depend on the ...

Pulmocide recently completed a Phase 2 safety and tolerability clinical trial (OPERA-S study) in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against pulmonary ...

A connection between lung health and kidney function in adults with cystic fibrosis (CF), identifying early urinary markers ...

2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by progressive scarring of the lungs, leading to respiratory failure and death. Therapies to treat IPF are ...